JP2021004194A - Emulsion composition - Google Patents
Emulsion composition Download PDFInfo
- Publication number
- JP2021004194A JP2021004194A JP2019117927A JP2019117927A JP2021004194A JP 2021004194 A JP2021004194 A JP 2021004194A JP 2019117927 A JP2019117927 A JP 2019117927A JP 2019117927 A JP2019117927 A JP 2019117927A JP 2021004194 A JP2021004194 A JP 2021004194A
- Authority
- JP
- Japan
- Prior art keywords
- emulsified composition
- content
- mass
- water
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 239000000839 emulsion Substances 0.000 title abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 17
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 10
- 229940099259 vaseline Drugs 0.000 claims abstract description 8
- 235000019271 petrolatum Nutrition 0.000 claims description 35
- 239000004264 Petrolatum Substances 0.000 claims description 32
- 229940066842 petrolatum Drugs 0.000 claims description 32
- 239000004204 candelilla wax Substances 0.000 claims description 12
- 235000013868 candelilla wax Nutrition 0.000 claims description 12
- 229940073532 candelilla wax Drugs 0.000 claims description 12
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 12
- 229930195733 hydrocarbon Natural products 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 150000002430 hydrocarbons Chemical class 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 8
- 239000001993 wax Substances 0.000 claims description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 7
- 239000004200 microcrystalline wax Substances 0.000 claims description 7
- 235000019808 microcrystalline wax Nutrition 0.000 claims description 7
- 239000012188 paraffin wax Substances 0.000 claims description 6
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 229960000735 docosanol Drugs 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 235000013869 carnauba wax Nutrition 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 12
- 230000005068 transpiration Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 21
- 239000004094 surface-active agent Substances 0.000 description 12
- 206010040880 Skin irritation Diseases 0.000 description 8
- -1 fatty acid ester Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000036556 skin irritation Effects 0.000 description 8
- 231100000475 skin irritation Toxicity 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229940056692 resinol Drugs 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 5
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229920001285 xanthan gum Polymers 0.000 description 5
- 239000000230 xanthan gum Substances 0.000 description 5
- 235000010493 xanthan gum Nutrition 0.000 description 5
- 229940082509 xanthan gum Drugs 0.000 description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011676 menaquinone-4 Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 229940114937 microcrystalline wax Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 description 1
- WAYLDHLWVYQNSQ-KEFDUYNTSA-N N-2-hydroxylignoceroylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC WAYLDHLWVYQNSQ-KEFDUYNTSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- RIQIJXOWVAHQES-UNAKLNRMSA-N Tocoretinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-UNAKLNRMSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- ZGBFGAHZKZQSLG-UMCOJZBLSA-N [30-oxo-30-[[(e,2s,3r,6r)-1,3,6-trihydroxyoctadec-4-en-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCC[C@@H](O)\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC ZGBFGAHZKZQSLG-UMCOJZBLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229940095137 ceramide 6 ii Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- FEZWOUWWJOYMLT-DSRCUDDDSA-M cobalt;[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,1 Chemical compound [Co].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FEZWOUWWJOYMLT-DSRCUDDDSA-M 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- PFIPZKASKUWLHH-UHFFFAOYSA-N pyridoxamine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CN)=C1O PFIPZKASKUWLHH-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000020955 thiamine monophosphate Nutrition 0.000 description 1
- 239000011621 thiamine monophosphate Substances 0.000 description 1
- GUGWNSHJDUEHNJ-UHFFFAOYSA-N thiamine(1+) monophosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N GUGWNSHJDUEHNJ-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、ワセリンを主成分とする乳化組成物に関する。 The present invention relates to an emulsified composition containing petrolatum as a main component.
皮膚の乾燥に起因する症状の治療、予防又は改善において、従来、皮膚の閉塞性を向上させ、皮膚からの水分蒸散を低減するために、ワセリンが基剤として使用されてきた。しかしながら、ワセリンは水を含有できないため、皮膚への水分の供給ができず、さらに、ワセリンは半固形状であるので、乾燥症状を示す皮膚に広範囲に塗布しづらく、塗布後のべたつき感が顕著であるため、使用感の点でも問題があった。 Vaseline has traditionally been used as a base in the treatment, prevention or amelioration of symptoms caused by dry skin in order to improve the obstructiveness of the skin and reduce the evaporation of water from the skin. However, since petrolatum cannot contain water, it cannot supply water to the skin, and since petrolatum is semi-solid, it is difficult to apply it widely to the skin showing dryness, and the sticky feeling after application is remarkable. Therefore, there was a problem in terms of usability.
このような問題を解決するために、ワセリンを含有する基剤として、乳剤、クリーム等の乳化組成物も使用されている。このような乳化組成物の製造においては、界面活性剤の使用が必須であるが、汎用されている界面活性剤には皮膚刺激性を示すものが少なくない。さらに、十分な皮膚の閉塞性と皮膚からの水分蒸散の低下効果を得るには、ワセリンの配合量を増やす必要があるが、それに伴って乳化に必要な界面活性剤の量が増加する。 In order to solve such a problem, an emulsifying composition such as an emulsion or a cream is also used as a base containing petrolatum. In the production of such an emulsified composition, the use of a surfactant is indispensable, but there are many widely used surfactants that exhibit skin irritation. Furthermore, in order to obtain sufficient skin occlusion and the effect of reducing water evaporation from the skin, it is necessary to increase the amount of petrolatum to be blended, and the amount of the surfactant required for emulsification increases accordingly.
乾燥症状を示す皮膚は、そのバリア機能が低下し、外からの刺激等に対して敏感な状態にある。このような皮膚が敏感な状態の消費者の使用に供するには、乳化組成物の皮膚刺激性を低減する必要がある。そのためには、皮膚刺激性が低い界面活性剤を用いるか、或いは界面活性剤の使用量を低減することが有効であると考えられる。しかしながら、皮膚刺激性が低い界面活性剤は乳化力の弱いものが多いため安定な乳化系が得られないことが多く、また界面活性剤の使用量を低減した場合にも、同様に乳化安定性の低下といった問題が生じていた。 The skin showing a dry symptom has a reduced barrier function and is in a sensitive state to external stimuli and the like. In order to be used by consumers with such sensitive skin, it is necessary to reduce the skin irritation of the emulsified composition. For that purpose, it is considered effective to use a surfactant having low skin irritation or to reduce the amount of the surfactant used. However, since many surfactants with low skin irritation have weak emulsifying power, a stable emulsifying system is often not obtained, and even when the amount of the surfactant used is reduced, the emulsifying stability is similarly obtained. There was a problem such as a decrease in.
従来、Ｗ／Ｏ型乳化組成物の安定性を向上する方法として、液状油性基剤に液状油性成分のゲル化剤を加えてゲル化させ、特定の油中水型界面活性剤により水と混合して乳化させる方法が知られている（特許文献１）。しかし、上記Ｗ／Ｏ型乳化組成物はゲル化剤としてデキストリン脂肪酸エステルのような油性ゲル化剤を用いるため、べたつきが生じ、使用感の面で課題があった。 Conventionally, as a method of improving the stability of a W / O type emulsified composition, a gelling agent of a liquid oily component is added to a liquid oily base to gelle it, and it is mixed with water by a specific water-in-oil surfactant. A method of emulsifying is known (Patent Document 1). However, since the W / O type emulsified composition uses an oily gelling agent such as a dextrin fatty acid ester as a gelling agent, stickiness occurs and there is a problem in terms of usability.
また、特許文献２及び３にも、高配合量のワセリン、グリセリン、皮膚刺激性の低いレシチンなどの界面活性剤を使用して得られる乳化組成物が開示されている。特許文献２及び３の乳化組成物に関しては、ワセリンの含有量が高配合になるため、べたつき感が強く、使用上の観点から望ましくない。特許文献３にも記載されているように、過酷な条件下での保存安定性に問題がある。 Further, Patent Documents 2 and 3 also disclose emulsified compositions obtained by using a surfactant such as petrolatum, glycerin, and lecithin having low skin irritation in a high blending amount. The emulsified compositions of Patent Documents 2 and 3 have a high content of petrolatum and therefore have a strong sticky feeling, which is not desirable from the viewpoint of use. As described in Patent Document 3, there is a problem in storage stability under harsh conditions.
特許文献４には流動パラフィン、スクワラン及び白色ワセリンからなる油性成分と、セレシンを乳化組成物全質量に対し高含有するＷ／Ｏ型乳化組成物が記されているが、セレシンなどの固形油類が多くなると、乳化組成物の安定性は増すが、乳化物が滑らかでなくなり、かつ使用感的にも好ましくない。 Patent Document 4 describes an oily component composed of liquid paraffin, squalane and white petrolatum, and a W / O type emulsified composition containing a large amount of selecin in the total mass of the emulsified composition. Solid oils such as selecin are described. Although the stability of the emulsified composition is increased, the emulsion becomes not smooth and is not preferable in terms of usability.
本発明の課題は、皮膚の閉塞性を向上させ、皮膚からの水分蒸散を低減するために十分な量のワセリンを含有しながらも使用感に優れ、皮膚に十分な水分を与えることが可能で、かつ持続的で良好な保湿性を有し、さらに低刺激性と保存安定性とを兼ね備えた乳化組成物を提供することにある。 The subject of the present invention is that it is possible to give sufficient moisture to the skin while having an excellent usability while containing a sufficient amount of petrolatum to improve the occlusiveness of the skin and reduce the evaporation of water from the skin. It is an object of the present invention to provide an emulsified composition which has a long-lasting and good moisturizing property, and further has both hypoallergenicity and storage stability.
本発明者らは、皮膚からの水分蒸散を低減するために十分な量の（A）ワセリンを含有し、皮膚刺激性の低い界面活性剤として（B）水素添加レシチンを含有し、また使用感触および組成物の安定性向上のために（C）固形油、（D）水、（E）水溶性高分子を含有するW/O型の乳化組成物を提供することにより、上記課題を解決することを見出した。 The present inventors contain a sufficient amount of (A) petrolatum to reduce water evaporation from the skin, (B) hydrogenated lecithin as a surfactant having low skin irritation, and a feeling of use. The above problems are solved by providing a W / O type emulsified composition containing (C) solid oil, (D) water, and (E) water-soluble polymer for improving the stability of the composition. I found that.
すなわち本発明は、（A）ワセリン、（B）水素添加レシチン、（C）固形油、（D）水、及び（E）水溶性高分子を含有するW/O型の乳化組成物で、かつ乳化組成物中で（A）ワセリンの含有量が最も多いことを特徴とする乳化組成物である。さらに、（B）水素添加レシチンの配合量が０．５〜５質量％であり、（C）固形油の含有量が０．１〜５質量％であり、（D）水の含有量が３０〜４５質量％未満であることを特徴とする乳化組成物である。 That is, the present invention is a W / O type emulsified composition containing (A) petrolatum, (B) hydrogenated lecithin, (C) solid oil, (D) water, and (E) water-soluble polymer. It is an emulsified composition characterized by having the highest content of (A) petrolatum among the emulsified compositions. Further, (B) the content of hydrogenated lecithin is 0.5 to 5% by mass, (C) the content of solid oil is 0.1 to 5% by mass, and (D) the content of water is 30. It is an emulsified composition characterized by being less than ~ 45% by mass.
本発明により、皮膚の閉塞性を向上させ、皮膚からの水分蒸散を低減するために十分な量のワセリンを含有しながらも使用感に優れ、皮膚に十分な潤いを与えることができ、かつ持続的で良好な保湿性を有し、低刺激性と保存安定性とを兼ね備える乳化組成物が提供される。また、本発明の乳化組成物は、保湿性にも優れるので、皮膚の乾燥に起因する症状、及び／又は皮膚の乾燥に起因する症状を示す疾患の治療、予防又は改善のための乳化組成物等として有用である。さらに、アトピー性皮膚炎等の症状の治療、予防又は改善のための組成物としても有用である。 According to the present invention, although it contains a sufficient amount of petrolatum to improve the obstructiveness of the skin and reduce the evaporation of water from the skin, it has an excellent usability, can sufficiently moisturize the skin, and lasts. An emulsified composition having good moisturizing properties, hypoallergenicity and storage stability is provided. Further, since the emulsified composition of the present invention is also excellent in moisturizing property, the emulsified composition for treating, preventing or ameliorating a symptom caused by dry skin and / or a disease showing a symptom caused by dry skin. It is useful as such. Furthermore, it is also useful as a composition for treating, preventing or ameliorating symptoms such as atopic dermatitis.
本発明で用いられるワセリンとしては、通常軟膏用途に広く用いられている、例えば、Sonneborn社のPerfectaなどの市販品ワセリンが挙げられる。好ましくは、特殊な水素化反応技術により精製された高品質のワセリンで、ワセリン中に微量含まれる不飽和化合物、芳香族化合物、硫黄化合物などの不純物が除去され、紫外線吸収の影響をほとんど受けず、物理的、化学的変化に対して安定で皮膚刺激がほとんどない、安全性に優れているワセリンとして、例えば、サンホワイトP-150（日興リカ株式会社）等が挙げられる。さらに好ましくは、ワセリン中に含まれる不純物をカラム吸着精製で処理した、無色で優れた酸化安定性と耐光性、軽い感触で優れた延びをし、従来のワセリンのべたつきを改善するとともに極性物質を除去することにより安全性の高いワセリンとして、例えばクロラータムV（クローダジャパン株式会社）のようなワセリンが挙げられる。 Examples of petrolatum used in the present invention include commercially available petrolatum such as Perfecta manufactured by Sonneborn, which is widely used for ointment applications. Preferably, it is a high-quality petrolatum purified by a special hydrogenation reaction technique, which removes impurities such as unsaturated compounds, aromatic compounds, and sulfur compounds contained in the petrolatum in trace amounts, and is hardly affected by ultraviolet absorption. Examples of petrolatum that is stable against physical and chemical changes, has almost no skin irritation, and has excellent safety include Sun White P-150 (Nikko Rika Co., Ltd.). More preferably, impurities contained in petrolatum are treated by column adsorption purification, which is colorless and has excellent oxidative stability and light resistance, and has excellent elongation with a light touch, improving the stickiness of conventional petrolatum and making polar substances. Examples of petrolatum that is highly safe by removing petrolatum include petrolatum such as Chloratum V (Clauder Japan Co., Ltd.).
さらに、本発明におけるワセリンは、石油から得た炭化水素類の混合物を脱色して精製したもので、分岐鎖を有するパラフィン（イソパラフィン）および脂環式炭化水素（シクロパラフィン、ナフテン）を含む半固形状の炭化水素類の混合物である。石油から得られる炭化水素類には常温で液体の流動パラフィンや、常温で固形の直鎖状炭化水素（ノルマルパラフィン）が主成分であるパラフィンワックス、分岐炭化水素（イソパラフィン）や飽和環状炭化水素（シクロパラフィン）が主成分であるマイクロクリスタリンワックスなどが存在する。本発明で用いるワセリンは、石油から得た炭化水素類の混合物を脱色して精製したもので、常温で半固形状のものであり、融点が40〜65℃の、石油から得た炭化水素類の混合物である。 Further, the petrolatum in the present invention is obtained by decolorizing and purifying a mixture of hydrocarbons obtained from petroleum, and is a semi-solid containing paraffin having a branched chain (isoparaffin) and an alicyclic hydrocarbon (cycloparaffin, naphthen). It is a mixture of hydrocarbons in shape. Hydrocarbons obtained from petroleum include liquid paraffin that is liquid at room temperature, paraffin wax whose main component is linear hydrocarbon (normal paraffin) that is solid at room temperature, branched hydrocarbon (isoparaffin), and saturated cyclic hydrocarbon (isoparaffin). There are microcrystalline wax and the like whose main component is (cycloparaffin). Vaseline used in the present invention is a mixture of hydrocarbons obtained from petroleum decolorized and refined. It is semi-solid at room temperature and has a melting point of 40 to 65 ° C., and hydrocarbons obtained from petroleum. Is a mixture of.
本発明におけるワセリンの含有量は、乳化組成物中の水の量より多く、通常、乳化組成物全量に対して４５〜６５質量％であり、好ましくは４５〜６０質量％であり、最も好ましくは４５〜５５質量％である。 The content of petrolatum in the present invention is larger than the amount of water in the emulsified composition, and is usually 45 to 65% by mass, preferably 45 to 60% by mass, and most preferably 45 to 60% by mass, based on the total amount of the emulsified composition. It is 45 to 55% by mass.
本発明における皮膚刺激性の低い界面活性剤の水素添加レシチンとしては、通常、大豆リン脂質や卵黄レシチンを水素添加したものが用いられる。例えば、水素添加大豆リン脂質としては、NIKKOLレシノールS-10（PC含量２５〜３０％）、NIKKOLレシノールS-10M（PC含量５５〜６５％）、NIKKOLレシノールS-10E（PC含量７５〜８５％）（日光ケミカルズ株式会社製）、またベイシスLP-20H（日清オイリオグループ株式会社製）、COATSOME NC-21（日油株式会社）なども利用することができる。
水素添加卵黄レシチンとしては、例えば卵黄レシチンPL-100P（キューピー株式会社）を利用することができる。
好ましくはNIKKOLレシノールS-10（PC含量２５〜３０％）、ベイシスLP-20H（日清オイリオグループ株式会社製）、卵黄レシチンPL-100P（キューピー株式会社）を利用することができる。さらに好ましくは、NIKKOLレシノールS-10（PC含量２５〜３０％）、卵黄レシチンPL-100P（キューピー株式会社）を利用することができる。
As the hydrogenated lecithin of a surfactant having low skin irritation in the present invention, a hydrogenated soybean phospholipid or egg yolk lecithin is usually used. For example, as hydrogenated soybean phospholipids, NIKKOL Resinol S-10 (PC content 25 to 30%), NIKKOL Resinol S-10M (PC content 55 to 65%), NIKKOL Resinol S-10E (PC content 75 to 85%) ) (Nikko Chemicals Co., Ltd.), Basis LP-20H (Nisshin Oillio Group Co., Ltd.), COATSOME NC-21 (Nichiyu Co., Ltd.), etc. can also be used.
As the hydrogenated egg yolk lecithin, for example, egg yolk lecithin PL-100P (Kewpie Corp.) can be used.
Preferably, NIKKOL lecithin S-10 (PC content 25 to 30%), Basis LP-20H (manufactured by Nisshin Oillio Group Co., Ltd.), and egg yolk lecithin PL-100P (Kewpie Corp.) can be used. More preferably, NIKKOL lecithin S-10 (PC content 25 to 30%) and egg yolk lecithin PL-100P (Kewpie Corp.) can be used.
水素添加レシチンの含有量は、乳化組成物全量に対して０．５〜５質量％が好ましく、さらに好ましくは１〜３．５質量％であり、最も好ましいのは１．５〜２．５質量％である。界面活性剤の含有量が少ない場合は乳化組成物の保存安定性が悪くなり、また逆に多すぎる場合は、乳化の状態が悪く滑らかな組成物が得られない。 The content of hydrogenated lecithin is preferably 0.5 to 5% by mass, more preferably 1 to 3.5% by mass, and most preferably 1.5 to 2.5% by mass with respect to the total amount of the emulsified composition. %. If the content of the surfactant is low, the storage stability of the emulsified composition is poor, and if it is too high, the emulsified state is poor and a smooth composition cannot be obtained.
本発明で用いられる固形油としては、常温で固形状の油性成分であればいずれでもよい。例えば、パラフィンワックス、セレシンワックス、マイクロクリスタリンワックス、モクロウ、モンタンワックスなどの炭化水素類、キャンデリラワックス、ミツロウ、ラノリンワックス、カルナウバワックスなどのロウ類、トリベヘン酸グリセリルなどの油脂類、ステアリン酸、ミリスチン酸、ベヘニン酸などの高級脂肪酸類、ステアリルアルコール、セチルアルコール、ベヘニルアルコールなどの高級アルコール類などが挙げられ、これらを１種又は２種以上組み合わせて用いることができる。本発明には好ましくは、セレシンワックス、マイクロクリスタリンワックス、キャンデリラワックス、カルナウバワックス、セチルアルコール、ベヘニルアルコールが利用でき、さらに好ましくはセレシンワックス、マイクロクリスタリンワックス、キャンデリラワックス、セチルアルコールが利用できる。 The solid oil used in the present invention may be any oily component that is solid at room temperature. For example, hydrocarbons such as paraffin wax, selecin wax, microcrystallin wax, mokurou, montan wax, waxes such as candelilla wax, beeswax, lanolin wax, carnauba wax, fats and oils such as glyceryl tribechenate, stearic acid, Examples thereof include higher fatty acids such as myristic acid and behenic acid, and higher alcohols such as stearic acid, cetyl alcohol and behenyl alcohol, and these can be used alone or in combination of two or more. Selecin wax, microcrystalline wax, candelilla wax, carnauba wax, cetyl alcohol, and behenyl alcohol can be preferably used in the present invention, and more preferably selecin wax, microcrystalline wax, candelilla wax, and cetyl alcohol can be used.
固形油の含有量は、乳化組成物全量に対して、通常は０．１〜５質量％、好ましくは０．５〜５質量％、より好ましくは１〜３質量％である。固形油の含有量が少ない場合は、乳化組成物が軟らかくなりすぎるとともに、保存安定性も悪くなる。また固形油の含有量が多くなりすぎると、乳化組成物の滑らかさがなくなり、使用感触的に悪い状態の乳化組成物になる。 The content of the solid oil is usually 0.1 to 5% by mass, preferably 0.5 to 5% by mass, and more preferably 1 to 3% by mass with respect to the total amount of the emulsified composition. When the content of the solid oil is low, the emulsified composition becomes too soft and the storage stability deteriorates. Further, if the content of the solid oil is too large, the smoothness of the emulsified composition is lost, and the emulsified composition is in a state of poor usability.
水の含有量は、乳化組成物全量に対して３０〜４５質量％未満であり、かつワセリンの含有量が水より多いことを特徴とする。このため、通常は、３０〜４５質量％未満、好ましくは３０〜４０質量％、より好ましくは３５〜４０質量％である。乳化組成物中の水の含有量が少なくなると、滑らかな使用感が無くなり、ワセリンのべたつき感が強くなり、良好な使用感の乳化組成物が出来なくなる。 The content of water is less than 30 to 45% by mass with respect to the total amount of the emulsified composition, and the content of petrolatum is higher than that of water. Therefore, it is usually less than 30 to 45% by mass, preferably 30 to 40% by mass, and more preferably 35 to 40% by mass. When the content of water in the emulsified composition is low, the smooth feeling of use is lost, the sticky feeling of petrolatum becomes strong, and the emulsified composition having a good feeling of use cannot be obtained.
本発明で用いられる水溶性高分子としては、メチルセルロース、エチルセルロース、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシエチルメチルセルロース、ヒドロキシプロピルセルロース等のセルロース系高分子；ポリビニルピロリドン、ポリエチレングリコール、カルボキシビニルポリマー、ポリビニルメチルエーテル等のビニル系高分子；ポリアクリル酸ナトリウム、ポリアクリル酸部分中和物、アクリル酸・メタクリル酸アルキルエステル共重合体等のアクリル酸系高分子；キサンタンガム、デキストラン、プルラン等の微生物系高分子；コンドロイチン硫酸、コンドロイチン硫酸ナトリウム、ヒアルロン酸、ヒアルロン酸ナトリウム等のムコ多糖類；等が挙げられる。これらの水溶性高分子は、１種単独で又は２種以上を組み合わせて使用できる。 Examples of the water-soluble polymer used in the present invention include cellulosic polymers such as methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose and hydroxypropyl cellulose; polyvinylpyrrolidone, polyethylene glycol, carboxyvinyl polymer, polyvinyl methyl ether and the like. Vinyl-based polymers; Sodium polyacrylate, partially neutralized polyacrylic acid, acrylic acid-based polymers such as acrylic acid / alkyl methacrylate copolymers; Microbial polymers such as xanthan gum, dextran, and purulan; Chondroitin Mucopolymers such as sulfuric acid, sodium chondroitin sulfate, hyaluronic acid, and sodium hyaluronate; and the like. These water-soluble polymers can be used alone or in combination of two or more.
本発明で用いられる水溶性高分子は、セルロース系高分子ではカルボキシメチルセルロース、ヒドロキシエチルセルロースが好ましく、ビニル系高分子ではポリビニルピロリドン、カルボキシビニルポリマーが好ましく、アクリル酸系高分子ではポリアクリル酸ナトリウム、アクリル酸・メタクリル酸アルキルエステル共重合体等が好ましく、微生物系高分子ではキサンタンガム、プルランが好ましく、ムコ多糖類ではヒアルロン酸、ヒアルロン酸ナトリウムが好ましい。中でも、カルボキシビニルポリマー、アクリル酸・メタクリル酸アルキルエステル共重合体、キサンタンガム、ヒアルロン酸ナトリウムが特に好ましい。 As the water-soluble polymer used in the present invention, carboxymethyl cellulose and hydroxyethyl cellulose are preferable for cellulosic polymers, polyvinylpyrrolidone and carboxyvinyl polymers are preferable for vinyl polymers, and sodium polyacrylate and acrylic are preferable for acrylic acid polymers. Acid / methacrylate alkyl ester copolymers and the like are preferable, xanthan gum and purulan are preferable for microbial polymers, and hyaluronic acid and sodium hyaluronate are preferable for mucopolysaccharides. Of these, carboxyvinyl polymers, acrylic acid / methacrylic acid alkyl ester copolymers, xanthan gum, and sodium hyaluronate are particularly preferable.
本発明における水溶性高分子の含有量は、本発明の効果を奏する限り特に制限されないが、乳化組成物全量に対して、通常０．０１〜３質量％、好ましくは０．０５〜１．５質量％であり、最も好ましいのは０．１〜１質量％である。 The content of the water-soluble polymer in the present invention is not particularly limited as long as the effects of the present invention are exhibited, but is usually 0.01 to 3% by mass, preferably 0.05 to 1.5% by mass based on the total amount of the emulsified composition. It is by mass, most preferably 0.1 to 1% by mass.
本発明の乳化組成物には、上記成分の他に、本発明の目的・効果を損なわない限りにおいて、通常化粧品に用いられる他の成分を必要に応じて適宜配合することができる。このような成分としては、油溶性高分子、高分子粉末、アルコール類、液体油脂、エステル油、炭化水素油、脂肪酸エステル、各種薬剤、有機変性粘土鉱物等が挙げられる。また、美白剤、抗シワ剤、保湿剤、抗炎症剤、酸化防止剤、防腐剤、ビタミン類などの有用成分を必要に応じて適宜配合することができるが、これら例示に限定されるものではない。 In addition to the above components, the emulsified composition of the present invention may be appropriately blended with other components usually used in cosmetics as long as the object and effect of the present invention are not impaired. Examples of such components include oil-soluble polymers, polymer powders, alcohols, liquid fats and oils, ester oils, hydrocarbon oils, fatty acid esters, various chemicals, and organically modified clay minerals. In addition, useful ingredients such as whitening agents, anti-wrinkle agents, moisturizers, anti-inflammatory agents, antioxidants, preservatives, and vitamins can be appropriately blended as needed, but are not limited to these examples. Absent.
例えば美白剤としては、プラセンタ、アルブチン、コウジ酸、ハイドロキノン、エチルアスコルビン酸、アスコルビン酸リン酸ナトリウム、アスコルビン酸リン酸マグネシウム塩、アスコルビン酸グルコシドなどのビタミンＣ類や、カンゾウエキス、ソウハクヒエキス等の植物に由来する成分；抗シワ剤としては、コエンザイムＱ１０等のユビキノン、カイネチン、アルジルリン、アセチルグルコサミン、コラーゲン、レチノール、パルミチン酸レチノール、レチナール、レチノイン酸、レチノイン酸トコフェリル、β−カロチン、酢酸トコフェロール；保湿剤としては、ポリエチレングリコール、トレハロース、ヘパリン類似物質、コラーゲン、エラスチン、尿素、ピロリドンカルボン酸ナトリウム等の天然保湿因子、セラミド１、セラミド２、セラミド３、セラミド４、セラミド５、セラミド６Ｉ、セラミド６ＩＩ、セラミド７等のセラミド類；抗炎症剤としては、カンゾウ抽出物、グリチルリチン酸ステアリル、グリチルリチン酸二カリウム、グリチルリチン酸モノアンモニウム等のグリチルリチン酸誘導体；グリチルレチン酸又はその誘導体；アラントイン又はその誘導体；抗酸化剤としては、トコフェロール、エチレンジアミン四酢酸二ナトリウム・二水和物、ソルビン酸、亜硫酸ナトリウム等；防腐剤としては、パラベン、安息香酸、デヒドロ酢酸ナトリウム、フェノキシエタノール、サリチル酸、プロパンジオール、プロピレングリコール、ブチレングリコール、ヘキサンジオール、カプリリルグリコール、エチルヘキシルグリセリン等；ビタミン類としては、リボフラビン、フラビンモノヌクレオチド、フラビンアデニンジヌクレオチドなどのビタミンＢ２誘導体、ニコチン酸メチル、ニコチン酸、ニコチン酸アミドなどのニコチン酸類；チアミン塩酸塩、チアミンモノリン酸塩等のビタミンＢ１類、塩酸ピリドキシン、塩酸ピリドキサール、ピリドキシン環状リン酸、塩酸ピリドキサミン等のビタミンＢ６類、シアノコバラミン、デオキシアデノシルコバラミン等のビタミンＢ１２類などが例示される。 For example, whitening agents include vitamin Cs such as placenta, albutin, coenzyme, hydroquinone, ethyl ascorbic acid, sodium ascorbic acid, magnesium ascorbic acid phosphate, and glucoside ascorbic acid, and plants such as citrus extract and soybean extract. Ingredients derived from; as anti-wrinkle agents, ubiquinone such as coenzyme Q10, kinetin, argylline, acetylglucosamine, collagen, retinol, retinol palmitate, retinal, retinoic acid, tocopheryl retinoate, β-carotene, tocopherol acetate; moisturizer Natural moisturizing factors such as polyethylene glycol, trehalose, heparin analog, collagen, elastin, urea, sodium pyrrolidone carboxylate, ceramide 1, ceramide 2, ceramide 3, ceramide 4, ceramide 5, ceramide 6I, ceramide 6II, ceramide. Ceramides such as 7; as anti-inflammatory agents, glycyrrhizic acid derivatives such as citrus extract, stearyl glycyrrhizinate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate; glycyrrhetinic acid or its derivatives; allantin or its derivatives; as antioxidants Tocopherol, disodium ethylenediamine tetraacetate / dihydrate, sorbic acid, sodium sulfite, etc .; as preservatives, paraben, benzoic acid, sodium dehydroacetate, phenoxyethanol, salicylic acid, propanediol, propylene glycol, butylene glycol, hexane Diol, caprylyl glycol, ethylhexyl glycerin, etc .; Examples of vitamins include vitamin B2 derivatives such as riboflavin, flavin mononucleotide and flavin adenin dinucleotide, nicotinic acids such as methyl nicotinate, nicotinic acid and nicotinic acid amide; thiamine hydrochloride, Examples thereof include vitamin B1s such as thiamine monophosphate, vitamin B6s such as pyridoxine hydrochloride, pyridoxal hydrochloride, pyridoxine cyclic phosphoric acid and pyridoxamine hydrochloride, and vitamin B12s such as cyanocobalamine and deoxyadenosylcobalamine.
本発明の乳化組成物の製造方法は、特段限定されることはなく、常用される方法で行えば良い。油相および水相を加温溶解し、撹拌を加えながら油相と水相を混合し、乳化する。乳化後、撹拌しながら室温まで冷却し、乳化組成物を得る。混合は、乳化剤の種類や量、また、製剤の使用目的等によってホモミキサー，コロイドミル，ホモジナイザー，プロペラ型ミキサーの乳化機を使用して行う。 The method for producing the emulsified composition of the present invention is not particularly limited, and it may be carried out by a commonly used method. The oil phase and the aqueous phase are heated and dissolved, and the oil phase and the aqueous phase are mixed and emulsified with stirring. After emulsification, the mixture is cooled to room temperature with stirring to obtain an emulsified composition. Mixing is performed using an emulsifier of a homomixer, a colloid mill, a homogenizer, or a propeller type mixer depending on the type and amount of emulsifier, the purpose of use of the preparation, and the like.
本発明について以下に実施例を挙げてさらに詳述するが、本発明はこれによりなんら限定されるものではない。含有量は特記しない限り質量％で示す。 The present invention will be described in more detail with reference to Examples below, but the present invention is not limited thereto. The content is shown in% by mass unless otherwise specified.
実施例の説明に先立ち、本発明で用いた評価試験の方法について説明する。 Prior to the description of the examples, the evaluation test method used in the present invention will be described.
（１）乳化組成物の状態
１０名の専門パネラーによる実使用性試験を行った。各乳化組成物を塗布した時、乳化組成物の状態が滑らかで、艶があることを以下の基準により判定した。
◎：１０名中、８名以上が滑らかで艶があると回答した。
○：１０名中、４〜７名が滑らかで艶があると回答した。
×：１０名中、３名以下が滑らかで艶があると回答した。
(1) State of emulsified composition An actual usability test was conducted by 10 specialized panelists. When each emulsified composition was applied, it was judged that the state of the emulsified composition was smooth and glossy according to the following criteria.
⊚: Out of 10 people, 8 or more answered that they were smooth and glossy.
◯: Of the 10 respondents, 4 to 7 responded that they were smooth and glossy.
X: Of the 10 respondents, 3 or less responded that they were smooth and glossy.
（２）乳化組成物を塗布したときの肌の閉塞性
１０名の専門パネラーによる実使用性試験を行った。各乳化組成物を塗布した時、乳化組成物が皮膚の閉塞性があることを以下の基準により判定した。
◎：１０名中、８名以上が皮膚の閉塞性が高いと回答した。
〇：１０名中、４〜７名が皮膚の閉塞性が高いと回答した。
×：１０名中、３名以下が皮膚の閉塞性が高いと回答した。
(2) Skin obstruction when the emulsified composition is applied An actual usability test was conducted by 10 specialized panelists. When each emulsified composition was applied, it was determined that the emulsified composition had skin obstruction according to the following criteria.
⊚: Of the 10 subjects, 8 or more responded that the skin was highly obstructive.
〇: Of the 10 subjects, 4 to 7 responded that the skin was highly obstructive.
X: Of the 10 subjects, 3 or less responded that the skin was highly obstructive.
（３）保存安定性
５０℃恒温器に放置し、乳化組成物の状態を観察し評価を行った。
◎：２週間以上放置しても良好な乳化状態を保った。
〇：１週間以上放置しても良好な乳化状態を保った。
×：良好な乳化状態を保てたのは１週間以下であった。
(3) Storage stability The mixture was left in an incubator at 50 ° C., and the state of the emulsified composition was observed and evaluated.
⊚: A good emulsified state was maintained even after being left for 2 weeks or more.
〇: A good emulsified state was maintained even if left for 1 week or longer.
X: Good emulsification was maintained for less than one week.
（表１に示した実施例１〜５、比較例１〜２の各乳化組成物の調製方法）
表１に示すアクリレーツ/アクリル酸アルキル(C10-30)クロスポリマー（Pemulen TR-2 Lubrizol Advanced Materials社）、プロパンジオール（Zemea Select DuPont Tate & Lyle Bio Products社）、L-アルギニン（味の素株式会社）に精製水を加えてよく分散し、約８０℃に加熱した。水素添加レシチン（NIKKOL レシノール S-10 日光ケミカル株式会社）、キャンデリラワックス（精製キャンデリラワックスMK-4 横関油脂工業株式会社）、マイクロクリスタリンワックス（Multiwax W-835 Sonneborn社）、ワセリン（クロラータムV クローダジャパン株式会社）からなる油相原料を約８０℃に加熱溶解し、水相に添加しホモミキサー処理をして乳化した。その後、冷却してW/O型の各乳化組成物を得た。
(Methods for preparing each emulsified composition of Examples 1 to 5 and Comparative Examples 1 and 2 shown in Table 1)
For Acrylate / Alkyl Acrylate (C10-30) Cross Polymer (Pemulen TR-2 Lubrizol Advanced Materials), Propanediol (Zemea Select DuPont Tate & Lyle Bio Products), L-Arginine (Ajinomoto Co., Inc.) shown in Table 1. Purified water was added, the mixture was well dispersed, and the mixture was heated to about 80 ° C. Hydrogenated lecithin (NIKKOL Resinol S-10 Nikko Chemical Co., Ltd.), Candelilla wax (refined candelilla wax MK-4 Yokoseki Yushi Kogyo Co., Ltd.), microcrystalline wax (Multiwax W-835 Sonneborn), Vaseline (Chloratum V Crowder) The oil phase raw material (Japan Co., Ltd.) was heated and dissolved at about 80 ° C., added to the aqueous phase, and treated with a homomixer to emulsify. Then, it was cooled to obtain each W / O type emulsified composition.
表１から明らかなように、水素添加レシチンを乳化組成物全体に対して０．５〜５質量％含有した組成物は、乳化状態の評価が高かったが、０．５質量％より含有量が低いものや、５質量％を超えて含有する場合は、乳化の状態が悪く滑らかで艶のある組成物が得られなかった。 As is clear from Table 1, the composition containing 0.5 to 5% by mass of hydrogenated lecithin with respect to the entire emulsified composition was highly evaluated for its emulsified state, but the content was higher than 0.5% by mass. When it was low or contained in excess of 5% by mass, the emulsified state was poor and a smooth and glossy composition could not be obtained.
（実施例６〜１０、比較例３〜４の各乳化組成物の調製方法）
表２に示すアクリレーツ/アクリル酸アルキル(C10-30)クロスポリマー（Pemulen TR-2 Lubrizol Advanced Materials社）、プロパンジオール（Zemea Select DuPont Tate & Lyle Bio Products社）、L-アルギニン（味の素株式会社）に精製水を加えてよく分散し、約８０℃に加熱した。水素添加レシチン（NIKKOL レシノール S-10 日光ケミカル株式会社）、キャンデリラワックス（精製キャンデリラワックスMK-4 横関油脂工業株式会社）、マイクロクリスタリンワックス（Multiwax W-835 Sonneborn社）、セレシン（日興リカ株式会社）、セタノール（高級アルコール工業株式会社）、ベヘニルアルコール（高級アルコール工業株式会社）、パラフィン（日興リカ株式会社）、ワセリン（クロラータムV クローダジャパン株式会社）からなる油相原料を約８０℃に加熱溶解し、水相に添加しホモミキサー処理をして乳化した。その後、冷却してW/O型の各乳化組成物を得た。
(Methods for preparing each emulsified composition of Examples 6 to 10 and Comparative Examples 3 to 4)
Acrylate / alkyl acrylate (C10-30) crosspolymer (Pemulen TR-2 Lubrizol Advanced Materials), propanediol (Zemea Select DuPont Tate & Lyle Bio Products), L-arginine (Ajinomoto Co., Inc.) shown in Table 2. Purified water was added, the mixture was well dispersed, and the mixture was heated to about 80 ° C. Hydrogenated lecithin (NIKKOL Resinol S-10 Nikko Chemical Co., Ltd.), Candelilla wax (refined candelilla wax MK-4 Yokoseki Yushi Kogyo Co., Ltd.), Microcrystalin wax (Multiwax W-835 Sonneborn), Celecin (Nikko Rika Co., Ltd.) Oil phase raw material consisting of Setanol (Higher Alcohol Industry Co., Ltd.), Behenyl Alcohol (Higher Alcohol Industry Co., Ltd.), Paraffin (Nikko Rika Co., Ltd.), Vaseline (Chloratum V Crowder Japan Co., Ltd.) is heated and dissolved at about 80 ° C. Then, it was added to the aqueous phase and treated with a homomixer to emulsify. Then, it was cooled to obtain each W / O type emulsified composition.
表２から明らかなように、本発明における固形油の含有量は、乳化組成物全量に対して１〜３質量％の範囲内である実施例１、実施例６−８では乳化組成物の状態が非常に良好、実施例９−１０では良好であったが、比較例３のように固形油を含まない場合は、乳化組成物が軟らかくなりすぎるとともに、保存安定性も悪くなった。また比較例４のように固形油の含有量が多くなりすぎると、乳化組成物の滑らかさがなくなり、状態の悪い乳化組成物になった。 As is clear from Table 2, the content of the solid oil in the present invention is in the range of 1 to 3% by mass with respect to the total amount of the emulsified composition. In Examples 1 and 6-8, the state of the emulsified composition. Was very good, and was good in Examples 9-10, but when the solid oil was not contained as in Comparative Example 3, the emulsified composition became too soft and the storage stability also deteriorated. Further, when the content of the solid oil was too large as in Comparative Example 4, the smoothness of the emulsified composition was lost, resulting in an emulsified composition in a poor state.
（実施例１、１１〜１２、比較例５〜７の各乳化組成物の調製方法）
表３に示すアクリレーツ/アクリル酸アルキル(C10-30)クロスポリマー（Pemulen TR-2 Lubrizol Advanced Materials社）、プロパンジオール（Zemea Select DuPont Tate & Lyle Bio Products社）、L-アルギニン（味の素株式会社）に精製水を加えてよく分散し、約８０℃に加熱した。水素添加レシチン（NIKKOL レシノール S-10 日光ケミカル株式会社）、キャンデリラワックス（精製キャンデリラワックスMK-4 横関油脂工業株式会社）、マイクロクリスタリンワックス（Multiwax W-835 Sonneborn社）、ワセリン（クロラータムV クローダジャパン株式会社）からなる油相原料を約８０℃に加熱溶解し、水相に添加しホモミキサー処理をして乳化した。その後、冷却してW/O型の各乳化組成物を得た。
(Methods for preparing each emulsified composition of Examples 1, 11 to 12 and Comparative Examples 5 to 7)
For Acrylate / Alkyl Acrylate (C10-30) Crosspolymer (Pemulen TR-2 Lubrizol Advanced Materials), Propanediol (Zemea Select DuPont Tate & Lyle Bio Products), L-Arginine (Ajinomoto Co., Inc.) shown in Table 3. Purified water was added, the mixture was well dispersed, and the mixture was heated to about 80 ° C. Hydrogenated lecithin (NIKKOL Resinol S-10 Nikko Chemical Co., Ltd.), candelilla wax (refined candelilla wax MK-4 Yokoseki Yushi Kogyo Co., Ltd.), microcrystalline wax (Multiwax W-835 Sonneborn), petrolatum (Chloratum V Crowder) The oil phase raw material (Japan Co., Ltd.) was heated and dissolved at about 80 ° C., added to the aqueous phase, and treated with a homomixer to emulsify. Then, it was cooled to obtain each W / O type emulsified composition.
表３から明らかなように、本発明における水の含有量は、乳化組成物全量に対して３０〜４５質量％未満の範囲内である実施例１、実施例１１−１２では乳化組成物の皮膚の閉塞性、乳化組成物の状態、保存安定性とも良好であったが、比較例５のように水の量が４５質量％より多い場合は、乳化組成物を皮膚に塗布したときの閉塞性が十分でなく、また、乳化組成物の保存安定性の評価も悪くなった。また、比較例６、７のように水の含有量が少なく、ワセリンの含有量が多い場合は、皮膚の閉塞性は高いが乳化組成物の状態、保存安定性とも悪い乳化組成物しかできなかった。 As is clear from Table 3, the water content in the present invention is in the range of less than 30 to 45% by mass with respect to the total amount of the emulsified composition. In Examples 1 and 11-12, the skin of the emulsified composition The obstructive property, the state of the emulsified composition, and the storage stability were all good, but when the amount of water was more than 45% by mass as in Comparative Example 5, the obstructive property when the emulsified composition was applied to the skin. Was not sufficient, and the evaluation of the storage stability of the emulsified composition was also poor. Further, when the water content is low and the petrolatum content is high as in Comparative Examples 6 and 7, only an emulsified composition having high skin obstruction but poor in terms of emulsified composition state and storage stability can be produced. It was.
（実施例１３〜１８の各乳化組成物の調製方法）
表４に示すアクリレーツ/アクリル酸アルキル(C10-30)クロスポリマー（Pemulen TR-2 Lubrizol Advanced Materials社）、カルボキシビニルポリマー（ハイビスワコー１０４ 富士フイルム和光純薬株式会社）、キサンタンガム（ノムコートZ 日清オイリオグループ株式会社）、ヒアルロン酸Na（ヒアルロン酸FCH-２００ キッコーマンバイオケミファ株式会社）、カルボキシメチルセルロース（CMC １１６０ ダイセルファインケム株式会社）、ヒドロキシエチルセルロース（HEC CF-W 住友精化株式会社）、プルラン（株式会社林原）、プロパンジオール（Zemea Select DuPont Tate & Lyle Bio Products社）と精製水、また必要に応じてL-アルギニン（味の素株式会社）を加えてよく分散し、約８０℃に加熱した。水素添加レシチン（NIKKOL レシノール S-10 日光ケミカル株式会社）、キャンデリラワックス（精製キャンデリラワックスMK-4 横関油脂工業株式会社）、マイクロクリスタリンワックス（Multiwax W-835 Sonneborn社）、ワセリン（クロラータムV クローダジャパン株式会社）からなる油相原料を約８０℃に加熱溶解し、水相に添加しホモミキサー処理をして乳化した。その後、冷却してW/O型の各乳化組成物を得た。
(Method for preparing each emulsified composition of Examples 13 to 18)
Acrylate / alkyl acrylate (C10-30) cross polymer (Pemulen TR-2 Lubrizol Advanced Materials), carboxyvinyl polymer (Hibiswaco 104 Fujifilm Wako Pure Chemical Industries, Ltd.), xanthan gum (Nomcoat Z Nisshin Oillio) shown in Table 4. Group Co., Ltd.), Na Hyaluronate (FCH-200 Hyaluronic Acid Co., Ltd.), Carboxymethyl Cellulose (CMC 1160 Daicel Fine Chem Ltd.), Hydroxyethyl Cellulose (HEC CF-W Sumitomo Seika Co., Ltd.), Pullulan (Co., Ltd.) Hayashihara), propanediol (Zemea Select DuPont Tate & Lyle Bio Products), purified water, and if necessary, L-arginine (Ajinomoto Co., Ltd.) were added to disperse well, and the mixture was heated to about 80 ° C. Hydrogenated lecithin (NIKKOL Resinol S-10 Nikko Chemical Co., Ltd.), candelilla wax (refined candelilla wax MK-4 Yokoseki Yushi Kogyo Co., Ltd.), microcrystalline wax (Multiwax W-835 Sonneborn), petrolatum (Chloratum V Crowder) The oil phase raw material (Japan Co., Ltd.) was heated and dissolved at about 80 ° C., added to the aqueous phase, and treated with a homomixer to emulsify. Then, it was cooled to obtain each W / O type emulsified composition.
表４から明らかなように、本発明に用いる水溶性高分子としては、アクリル酸・メタクリル酸アルキルエステル共重合体、カルボキシビニルポリマー、キサンタンガム、ヒアルロン酸ナトリウムを０．１〜１質量％用いることで非常に良好な状態の乳化組成物が得られることが明らかとなった。また、カルボキシメチルセルロース、ヒドロキシエチルセルロース、プルランを用いることによっても良好な状態の乳化組成物が得られた。 As is clear from Table 4, as the water-soluble polymer used in the present invention, 0.1 to 1% by mass of acrylic acid / methacrylic acid alkyl ester copolymer, carboxyvinyl polymer, xanthan gum, and sodium hyaluronate is used. It was revealed that an emulsified composition in a very good condition can be obtained. Further, an emulsified composition in a good state was also obtained by using carboxymethyl cellulose, hydroxyethyl cellulose and pullulan.
本発明により、ワセリンを高含有する乳化組成物において、皮膚安全性が高く、かつ乳化状態が良く、保存安定性に優れた乳化組成物の提供が可能となった。本乳化組成物は、肌荒れにより水分保持能が低下した皮膚や、アトピー性皮膚炎の患者にも有用な乳化組成物である。
INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an emulsified composition containing a high amount of petrolatum, which has high skin safety, a good emulsified state, and excellent storage stability. This emulsified composition is also useful for patients with atopic dermatitis and skin whose water retention capacity is reduced due to rough skin.
Claims (7)
（B）水素添加レシチン、
（C）固形油、
（D）水、及び
（E）水溶性高分子
を含有し、（B）水素添加レシチンの含有量は０．５〜５質量％であり、（C）固形油の含有量は０．１〜５質量％であり、（D）水の含有量は３０〜４５質量％未満であり、W/O型である乳化組成物。 (A) Vaseline,
(B) Hydrogenated lecithin,
(C) Solid oil,
It contains (D) water and (E) a water-soluble polymer, (B) the content of hydrogenated lecithin is 0.5 to 5% by mass, and (C) the content of solid oil is 0.1 to 1. An emulsified composition of 5% by mass, (D) water content of less than 30-45% by mass, and W / O type.
The water-soluble polymer (E) is at least one polymer selected from the group consisting of a cellulosic polymer, a vinyl polymer, an acrylic acid polymer, a microbial polymer, and a mucopolysaccharide. The emulsified composition according to any one of claims 1 to 6, characterized in that.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019117927A JP7482496B2 (en) | 2019-06-25 | 2019-06-25 | Emulsion composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019117927A JP7482496B2 (en) | 2019-06-25 | 2019-06-25 | Emulsion composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021004194A true JP2021004194A (en) | 2021-01-14 |
| JP7482496B2 JP7482496B2 (en) | 2024-05-14 |
Family
ID=74099560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019117927A Active JP7482496B2 (en) | 2019-06-25 | 2019-06-25 | Emulsion composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7482496B2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008201691A (en) * | 2007-02-19 | 2008-09-04 | Takada Seiyaku Kk | Emulsion base, external preparation using the same and emulsion composition |
| JP2009046472A (en) * | 2007-07-20 | 2009-03-05 | Rohto Pharmaceut Co Ltd | Emulsified composition |
| JP2009256377A (en) * | 2007-07-20 | 2009-11-05 | Rohto Pharmaceut Co Ltd | Method for preparing emulsion composition |
| JP2016222544A (en) * | 2015-05-26 | 2016-12-28 | ロート製薬株式会社 | External skin preparation |
-
2019
- 2019-06-25 JP JP2019117927A patent/JP7482496B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008201691A (en) * | 2007-02-19 | 2008-09-04 | Takada Seiyaku Kk | Emulsion base, external preparation using the same and emulsion composition |
| JP2009046472A (en) * | 2007-07-20 | 2009-03-05 | Rohto Pharmaceut Co Ltd | Emulsified composition |
| JP2009256377A (en) * | 2007-07-20 | 2009-11-05 | Rohto Pharmaceut Co Ltd | Method for preparing emulsion composition |
| JP2016222544A (en) * | 2015-05-26 | 2016-12-28 | ロート製薬株式会社 | External skin preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7482496B2 (en) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5373381B2 (en) | Cosmetic composition and cosmetic treatment method using the cosmetic composition | |
| WO2010044261A1 (en) | Skin preparation composition for external use | |
| WO2010113930A1 (en) | External preparation for skin | |
| JP2010120857A (en) | Skin external preparation | |
| JP6057461B2 (en) | Alpha gel structure and cosmetic or skin external preparation containing the same | |
| JP6904754B2 (en) | Oil-in-water emulsified composition | |
| DE19852212A1 (en) | Compositions of emulsion type W / O having an increased water content, further comprising one or more alkyl methicone copolyols and / or alkyl dimethicone polyols and cationic polymers | |
| WO2003097072A1 (en) | Chloasma amelioration composition and dullness amelioration composition | |
| JP2006290762A (en) | Oil-in-water emulsified composition | |
| WO2012017733A1 (en) | Skin cosmetic | |
| JPH0567125B2 (en) | ||
| KR20190036341A (en) | Cosmetic Composition for Reducing Stickiness and Improving Transparency of Emulsion Formulation | |
| JP2003003013A (en) | Oil-in-water emulsifier composition composed of alkylated polysaccharide and cosmetic using the same | |
| WO2013021775A1 (en) | Liquid skin-conditioning composition | |
| JP2023181387A (en) | External composition including azelaic acid, and method for producing the same | |
| WO2020137785A1 (en) | Retinol-containing oil-in-water type emulsified cosmetic material | |
| JP2016166187A (en) | Oil-in-water emulsion cosmetics | |
| JP2021004194A (en) | Emulsion composition | |
| JP2013159605A (en) | Skin preparation composition for external use | |
| JP4282358B2 (en) | W / O / W emulsion external composition for skin and method for producing the same | |
| DE102004010246A1 (en) | Emulsion based cosmetic and/or dermatological preparation, useful for e.g. reducing the transepidermal water loss and prophylaxis and treatment of the symptoms of skin aging, comprises 22-28C fatty acid and a polar lipid phase | |
| JP5641665B2 (en) | External preparation for skin and method for producing the same | |
| JP2020100609A (en) | Gel-like cosmetic | |
| JP2004536837A (en) | Folic acid-containing personal care products | |
| JP2000204046A (en) | External medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220621 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240321 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240422 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7482496 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |